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Background: Fatigue and sleep disturbance are two of the most common and distressing cancer 
symptoms that negatively affect quality of life. 
Objective: To assess the prevalence of, and factors contributing to, fatigue and sleep disturbance in 
Arabic-speaking cancer patients in Oman following completion of their cancer treatment. 
Methods: A cross-sectional and descriptive correlational design was used. Data were collected using 
the Pittsburgh Sleep Quality Index (PSQI ˃5), the Functional Assessment of Cancer Therapy- Fatigue 
(FACT-F ≤ 34) and the Functional Assessment of Cancer Therapy – General. 
Results: Of the 369 patients that participated, 77.5% (n=286) reported clinically-significant fatigue, 
and 78% (n=288) reported poor sleep. Fatigue (P<.05) was significantly associated with age, cancer 
site, months since diagnosis, type of treatment received, and comorbidity. Those experiencing fatigue 
and poor sleep had the lowest quality of life among the cancer patients studied. 
Conclusion: Fatigue and sleep disturbance are significant problems for the Arabic patients diagnosed 
with cancer. Both fatigue and sleep disturbance should be routinely assessed in the case of such 
patients. 
Implications for Practice: Routine assessments of fatigue and sleep disturbance are recommended so 
that appropriate interventions and treatment management plans can be introduced to reduce fatigue and 







Cancer is a major life stressor that can affect the physiological, psychological and physical state of the 
person diagnosed. The cancer journey can involve pain, weakness and fatigue, and can reduce 
functioning in terms of active daily living. The World Health Organization estimates that there were 
24.5 million cases of newly-diagnosed cancer, and over 9.6 million deaths in 2017. 1 The number of 
new cancer diagnoses is expected to rise in the next two decades by about 70% globally. 2 In Oman, 
more than 1,615 patients were diagnosed with cancer in 2015. 3 
In a review of 37 research articles, Wu and Harden 4 identified that fatigue, depression, sleep 
disturbance and pain symptoms were experienced by more than one-third of cancer survivors after 
treatment. The prevalence of cancer-related fatigue is estimated at between 50% and 92%. 5 Fatigue has 
been shown to negatively affect daily activity levels and quality of life (QoL). 6,7 Jones et al. 8 reported 
that fatigue is also associated with high levels of disability. 
In the current study, three definitions were adopted. First, Cella et al.9 defined fatigue as ‘…a 
subjective state of overwhelming and sustained exhaustion and decreased capacity for physical and 
mental work that is not relieved by rest’. Second, Buysse 10 defined sleep health as ‘…a 
multidimensional pattern of sleep-wakefulness, adapted to individual, social, and environmental 
demands, that promotes physical and mental well-being’. Last, Cella 11 described QoL as ‘…the extent 
to which one's usual or expected physical, emotional, and social well-being are affected by a medical 
condition or its treatment’. 
Fatigue may occur during treatment for cancer; it typically increases during radiation therapy12, 
chemotherapy 13 and biological therapy.14 In addition, even after completion of primary treatment, 
fatigue persists in more than 50% to 65% of patients, for months or even years.15,16 It is important to 
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study the incidence of fatigue in various populations to establish cultural variations and to establish 
normative data in specific populations. 
Patients diagnosed with cancer often experience sleep disturbance, particularly insomnia. Sleep 
disturbance affects between 50% to 75% of cancer patients.17 It has also been linked to the likelihood 
of cancer recurrence 18,19 and may result in poor healing, 20 decreased cognitive functioning,21 and 
reduced work activity.22  In addition, sleep disturbance in cancer patients can negatively impact their 
health-related QoL, which includes physical and psychological functioning.23,24 
Rationale of the Study 
In the Omani population, there are no published data on the prevalence of fatigue, sleep disturbance 
and/or altered QoL in cancer patients. In addition, the Gulf countries that have the same culture and 
share the same language (Arabic) have not published studies that address fatigue and sleep disturbance 
in cancer patients.  Omani cancer patients share the same values, culture and beliefs as patients living 
in many other Arabic countries; however, most studies on fatigue, sleep disturbance and QoL have 
been conducted in Western cultures. The subjective nature of patients’ reported assessments of their 
symptoms might be different in Arabic countries. This study focused on the prevalence of fatigue, 
sleep, and QoL within an Arabic culture to provide prevalence information with regard to fatigue, sleep 
disturbance, and QoL within Arabic-speaking cancer patients in Oman.  
Study Aims 
The aims of this study were to (1) assess the prevalence of, and factors contributing to, fatigue and 
sleep disturbance in Arabic-speaking cancer patients in Oman following completion of their cancer 
treatment, and (2) assess their fatigue in relation to sleep disturbance, health-related QoL, 




Study Design and Sample 
A quantitative design incorporating a cross-sectional survey was used. Participants were recruited from 
the National Oncology Centre’s outpatient clinic from November 2017 to January 2019. The inclusion 
criteria for participating in the study were: adult patients above 18 years of age; able to speak and write 
in Arabic;  no known psychiatric or neurological disorders that could interfere with study participation 
(such as schizophrenia or Parkinson’s disease); diagnosed with any type of cancer; and completed 
surgical intervention, chemotherapy and/or radiotherapy treatment at least one month prior to 
recruitment, but during the last 12 months. Exclusion criteria included being less than 18 years of age, 
currently undergoing chemotherapy or radiotherapy treatment, or newly diagnosed with cancer.  
Instrument Used  
Demographic data and treatment characteristics were collected from patients. The study used three 
instruments to measure fatigue, sleep disturbance, and QoL.   
Fatigue 
The Functional Assessment of Cancer Therapy-Fatigue subscale (FACT-F), consisting of 13-items, 
assesses self-reported fatigue in the previous seven days.25 The response options from the 5-point 
Likert scale for each item range from 0 to 4. The total score of the FACT-F ranges from 0 to 52. A 
higher score indicates less or no fatigue, whereas a lower score indicates more fatigue. Van Belle et al. 
26 identified the cut-off point of the FACT-F value as 34 for a diagnosis of fatigue in patients with 
cancer, with a score equal to or less than 34 indicating clinically-significant fatigue. The original 
FACT-F showed strong internal consistency (coefficient alpha 0.93-0.95) and good stability (test-retest 
r =0.87).25 The Arabic version of FACT-F showed very good internal consistency (Cronbach’s α = 
.94). 27  
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Quality of Life 
The Functional Assessment of Cancer Therapy-General (FACT-G) version 4 28,29 measures QoL using 
27-items that are divided into four domains: physical well-being (PWB) (7-items); social/family well-
being (SWB) (7-items); emotional well-being (EWB) (6-items); and functional well-being (FWB) (7-
items). Each sub-scale score can be calculated separately if more than 50% of the items are answered. 
The response options from the 5-point Likert scale for each item range from 0 to 4. The total score is 
calculated by summing all individuals’ sub-scales (PWB+SWB+EWB+FWB); the total score can range 
from 0 to 108. A higher score indicates a good level of QoL, whereas a lower score indicates a reduced 
level of QoL. The Cronbach’s α value of the Arabic version of FACT-G is .92. 27   
Sleep Quality 
The Pittsburgh Sleep Quality Index (PSQI) was used to assess sleep quality over the previous month.30 
The PSQI consists of 19-items categorized into seven components: subjective sleep quality, sleep 
latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications and 
daytime dysfunction. The score of each of the seven components can range from 0 to 3. The global 
score of the PSQI is calculated by summing the seven components, which can range from 0 to 21, with 
higher scores indicating poor sleep quality in the previous month. If the global score was more than 
five, then the participants were classified as experiencing poorer sleep; if the score was less than or 
equal to five, they were classified as experiencing good sleep. The PSQI has acceptable reliability in 
terms of Arabic cancer patients (Cronbach’s α = .77).31 
Data Analysis 
The data were entered into the Statistical Package for the Social Science (SPSS), version 25. In order to 
address the research questions, descriptive statistics were calculated in the form of means, standard 
deviations, standard errors, frequency, and percentages for all the scales, sub-scales and participant 
variables. Independent t-test and chi-squares (or Fisher’s exact test) were used to test whether or not the 
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levels of fatigue, sleep quality and QoL differed in terms of demographics and treatment 
characteristics. 
Two separate logistic regressions were conducted. The first was to identify the association of 
(demographic, treatment characteristic, PSQI seven components, and FACT-G subscales) factors that 
predict significant fatigue in patients (FACT-F ≥34) diagnosed with cancer. The second was to identify 
the predicting variables of ‘poorer sleep’ (PSQI ˃5) using the demographic, treatment characteristic, 
FACT-F, and FACT-G sub-scales variables. The Hosmer-Lemeshow test was applied to assess the 
model’s goodness-of-fit test.  P>.05 was considered to be statistically significant for all analyses.  
Ethical Considerations 
Ethical permission was sought initially from the Nursing and Health Research Institute Filter 
Committee at Ulster University. As the research was conducted in the National Oncology Centre of the 
Royal Hospital in Oman, ethical approval was also sought from the Ministry of Health in Oman via the 
Research and Ethical Review and Approval Committee in the Directorate General of Planning and 
Studies at the Ministry of Health (MoH/DGPS/CSP/PROPOSAL_ APPROVED/31/2017). 
Results 
Demographic and Treatment Characteristics  
Of the 400 patients eligible to participate, 369 participants completed and returned valid questionnaire 
booklets, giving a response rate of 92.2%. Thirty-one patients were not included in the study; thirteen 
did not return the questionnaire booklet, eleven declined to participate, and seven did not complete 
enough of the questionnaire booklet for their responses to be included. 
The majority of the participants were female (66.4%, n=245), and the largest age group was 41-50 
years of age (25.7%, n=95), followed by 31-40 years (22.8%, n=84). Approximately three-quarters of 
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the participants were married 74% (n=273), with single participants accounting for 10.8% (n=40) 
(Table 1). 
The most frequent cancer sites were breast 37.7% (n=139) and colorectal (14.6%, n=54). The tumor 
stages ranged from 1 to 4 and unspecified; most participants had stage II cancers (39.3% n=145). 
Furthermore, 42.5% (n=157) of the participants had been diagnosed within the previous year, whereas 
34.4% (n=127) were diagnosed 12 to 24 months previously. Most participants, (63.4%, n=234), had 
received both chemotherapy and radiotherapy. More than half (52.3% n=193) of the participants did 
not have previous medical problems. 
Prevalence of Fatigue 
In the total group, the mean fatigue score was 22.70 (SD. 12.99, 0-52). Of the 369 patients, 286 
(77.5%) experienced clinically-significant fatigue (FACT-F ≤ 34) and 83 (22.5%) were not fatigued. 
There were significant differences in fatigue by age (ꭓ2 (4, N=369) =14.399, p=.006) with the highest 
proportion of fatigue found among participants aged between 51 and 60 (22.7% vs. 13.3%), and among 
those over 60 (24.1% vs. 10.8%) compared with the non-fatigue groups. There were also significant 
differences in fatigue (ꭓ2 (9, N=369) =18.276, p=0.032) according to cancer site; participants with 
colorectal, lung, gastrointestinal, brain, gynecological, and lymphoma were more likely to have fatigue 
compared to non-fatigue groups.  
Fatigue differed significantly in relation to the number of months since diagnosis (ꭓ2 (8, N=369) =8.65, 
p=.034); participants diagnosed with cancer within the previous twelve months were more likely to 
have fatigue (46.2% vs. 31.2%). There were significant differences in cases of fatigue according to the 
type of treatment (ꭓ2 (2, N=369) =10.791, p=.005) with the highest proportion of fatigue found among 
participants treated with both chemotherapy and radiotherapy (67.8% vs. 48.2%) compared to the non-
fatigue groups. Fatigue was more prevalent among patients with asthma (2.8% vs. 0%), anemia (4.5% 
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vs. 0%), hypertension/heart failure (18.2% vs. 10.8%), diabetes/heart diseases (18.9% vs. 7.2%), and 
others (3.8% vs. 2.4%) when compared to non-fatigue groups. There were no differences in fatigue 
according to gender (p=.41), marital status (p=.26), education level (p=.56), employment status (p=.15) 
and stage of cancer (p=.60).  
Participants with fatigue reported lower mean scores of the QoL scale and sub-scales compared to non-
fatigue patients (Table 2). In addition, in the fatigue groups (M=10.23, SD=3.99), the level of PSQI 
was lower compared to that in the non-fatigue groups (M=5.76, SD=2.95), t (177.758) =11.15, p<.05, 
indicating that fatigue is related to poor sleep. Among the seven sub-scales of the PSQI, there were six 
significantly associated with worse fatigue: subjective sleep quality, sleep latency, habitual sleep 
efficiency, sleep disturbances, use of sleep medications and daytime dysfunction. Only sleep duration 
was not statistically significantly associated with fatigue (P=.06). 
Prevalence of Sleep Disturbance 
The mean PSQI score was 9.22 (SD, 4.2, ranging from 1 to 20) and the prevalence of poorer sleep 
among participants was 78% (n=288) using a cut-off score of 5, which is the clinically significant 
indication of poorer sleep. There were no differences in reporting poor sleep according to gender 
(p=.36), age (p=.14), education level (p=.77), employment status (p=.36), stage of cancer (p=.15) and 
time since diagnosis (p=.78). Marital status had a significant influence on the poor sleep group ꭓ2 (2, 
N=369) =8.583, p=.014, with a higher prevalence of married (74.3% vs. 72.8%) and 
divorced/separated/widowed (17% vs. 8.6%) participants being identified as poorer sleepers compared 
to the good sleepers group. Finally, significant effects on sleep were associated with cancer site (ꭓ2 (9, 
N=369) =17.163, p=.04), with poorer sleep associated with colorectal, stomach, lung, gastrointestinal, 
brain, lymphoma and gynecological cancers. 
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There were significant differences observed in patients receiving both chemotherapy and radiotherapy 
(66.7% vs. 51.9%) compared with other treatments (ꭓ2 (2, N=369) =10.044, p=.007) who reported poor 
sleep. Participants with asthma, anemia, hypertension/heart failure, diabetes/heart diseases and other 
comorbidities were more likely to report poor sleep (ꭓ2 (6, N=369) =24.961, p=.001) compared to good 
sleepers. 
Participants with poorer sleep had significantly lower fatigue scores (M=19.4, SD=14.2) than good 
sleepers (M=34.38, SD=11.63), t (10.41) =367, p<0.05), indicating that poor sleepers had reported 
more fatigue. The poorer sleep had significantly lower mean scores for QoL (M=64.64, SD=16.9) as 
well as PWB (M=10.1, SD=7.61), EWB (M=14.08, SD=5.47) and FWB (M=18.28, SD=5.42) 
compared to good sleeper groups (p<.05). Only the SWB subscale demonstrated no significant 
difference between the two sleep quality groups (Table 3). 
Predictive Factors for Fatigue  
All the variables were selected to form a logistic regression model. Twelve independent variables were 
significantly associated with fatigue (Table 4). The strongest predictor of fatigue was the number of 
months since diagnosis; those with fewer than 12 months were 10.9 times more likely to suffer fatigue 
(95% CI:1.369-86.820; p=.024). The second predictor of fatigue was employment status; employed 
participants were 9.6 times more likely to suffer fatigue (95% CI: 1.583-58.934; p=.014). Participants 
with sleep latency or sleep disturbance issues were 3.5 times (95% CI: 1.715-7.309; p=.001) and 2.7 
times (95% CI: 1.079-6.820; p=.034) respectively, to be more likely to experience fatigue. Social and 
family well-being also significantly predicted fatigue, as participants were twice as likely to exhibit 
fatigue if they had social problems.  
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Predictive Factors for Poor Sleepers 
All the variables were selected to form a logistic regression model. Four independent variables were 
significantly associated with sleep disturbances (Table 5). The strongest predictor of sleep disturbances 
was age; those between 18 and 30 years of age were 10 times more likely to have sleep disturbances 
than was revealed in the case of other variables (95% CI:1.093-93.091; p=.042). The other predictors 
were single marital status and PWB. The fatigue scale mean significantly predicted poor sleepers (aOR: 
0.929, CI; 0.887-0.974).  
Discussion 
To the best of our knowledge, this is the first study to examine the prevalence of fatigue, sleep 
disturbance and QoL among Arabic cancer patients in Oman following treatment. The main findings 
indicate that over 77% of the patients in this study experienced clinically-significant fatigue. These 
results are higher than those found in previous studies reporting post-treatment fatigue in diverse cancer 
populations, with rates varying from 39% in the Netherlands 32 to 60% in the United States,33 a 
difference that may be partially explained by the majority of participants (63.4%) having received 
combined chemotherapy and radiotherapy. This is consistent with other studies which have found that 
survivors treated with combined radiotherapy and chemotherapy are at higher risk of increased 
fatigue.8,34 Boer et al.35 suggested that combined radiotherapy and chemotherapy was more toxic than 
chemotherapy alone. 
The prevalence of fatigue in Arabic cancer patients in Oman was influenced by age, with fatigue being 
significantly more prevalent in patients over the age of 51. Previous research also indicated that older 
patients with cancer report more fatigue than younger patients.36,37  Giacalone et al. 38 suggested that 
elderly people who have survived cancer, but who live with comorbidity conditions, may have an 
increased prevalence of fatigue. In our study, 67.6% (119/176) of participants over the age of 51 years 
reported comorbidities; moreover, comorbidities (asthma, anemia, hypertension/heart failure and 
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diabetes/heart diseases) were significantly associated with the increased prevalence of fatigue. There 
may be unique features of certain types of cancer and cancer treatment strategies that increase the 
probability of experiencing fatigue. In the current study, participants diagnosed with colorectal, 
gastrointestinal, lymphoma and gynecological cancers reported a significantly greater prevalence of 
fatigue compared with individuals with other cancers. Other studies have similarly found that fatigue 
varies by cancer type.39,40 This may be attributable to the type of cancer treatment and management. 
The findings of the current study demonstrate decreased fatigue over time following a diagnosis; 
participants diagnosed with cancer within the previous twelve months were more likely to have fatigue 
than those with a diagnosis of a year or longer. Wang et al.41 and Matias et al. 42 have indicated that 
fatigue decreases after the second year from diagnosis. Persistent fatigue in cancer survivors might be 
linked to chronic inflammatory processes. 43  
Fatigue has deleterious effects on QoL, as the patients feel tired and lack the energy to perform daily 
activities. The results of this study indicate a significant association between fatigue and all the mean 
scores of the QoL scale, and the PSQI subscales and global score. Participants with fatigue report lower 
levels of QoL and increased sleep disturbance. Previous studies have indicated the direct influence of 
fatigue in lowering QoL and causing disturbed sleep on the part of patients diagnosed with cancer.44–46 
Therefore, this work supports the findings from previous studies in different populations.  
Sleep Disturbance  
The mean global PSQI score in the current study was 9.18 (SD=3), similar to findings within other 
populations, including in Danish (7.01(SD=3.89) 47 and Iranian (8.97(SD=2.96) samples. 48 The 
prevalence of sleep disturbances (PSQI >5) was 78%, which is higher than the findings by George et 
al. 44 who reported sleep difficulty as 64% (total sample size n=256), but comparable to the estimates 
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by Wu et al., 49 who reported the percentage of sleep difficulty in cancer survivors as 77.3% (total 
sample size n=44); both studies were conducted in United States. 
Poor sleep quality was significantly higher in patients who received both chemotherapy and radiation 
therapy in their primary treatment. Moreover, comorbidities had a significant impact on sleep. Many 
factors can contribute to sleep difficulties such as chemotherapy, radiation therapy and 
comorbidities.50,51 There are a number of demographic and treatment characteristic variables previously 
reported as being associated with an increased rate of sleep disturbance such as gender, age, education 
level, employment status, cancer site, stage of cancer and time since diagnosis; 17,52,53 however, in this 
study, these variables were not statistically significantly associated with sleep disturbance.  There may 
be unique features of sample characteristics between studies, for example certain types of cancer and 
cancer treatment strategies, that increase the association of sleep disturbance with different variables. 
This study has found that poor sleepers had low overall QoL and that fatigue has a significant effect on 
sleep disturbance. A similar result was reported by Van Leeuwen et al., 24 George et al.,44and Dickerson 
et al.,49. Sleep disturbance appears to contribute to fatigue. Understanding the underlying causes of both 
fatigue and sleep disturbance is essential for improving interventions that can help to reduce the 
symptoms and improve the QoL of cancer survivors.  
In this study, time, specifically the first 12 months after a diagnosis, was the most robust predictor of 
fatigue. Moreover, it was found that fatigue was predicted by all QoL subscales; physical, 
social/family, emotional and functional well-being. These findings are in line with other research 
describing the prediction of fatigue in association with similar variables.23,55  In the present study, 
marital status (single), the PWB subscale and fatigue predicted sleep disturbance. Otte et al. 56 
documented that sleep disturbance was less likely to occur in individuals who were married. This may 
be because single patients (unmarried) may have less social and emotional support, thus leading to 
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loneliness and poor sleep.57,58 However, the family structure in Oman is different from that found in 
many other countries; around 60% consist of an extended family cohabitating, such as a single person 
living with parents, grandparents, brothers, sisters, and sometimes married brothers with children all 
living in the same home with a grandparent or in an adjacent house.59 Further study is required to 
identify the factors that affect sleep disturbance among single patients with cancer. Our results suggest 
that poor sleep quality and fatigue could impede the ability of cancer patients to function in daily life. 
Limitations 
The study has a number of limitations. The study utilized a cross-sectional design, and therefore 
findings represent fatigue, sleep disturbance and QoL at one point in time. The study relied on the 
participants’ self-reporting, without any objective metrics to support the self-reports. The inclusion 
criteria might have contributed to selection bias because only participants who had completed surgical 
intervention, chemotherapy and/or radiotherapy treatment, either at least one month prior to recruitment 
or during the previous 12 months, were included. Another study limitation was sample heterogeneity, 
as different types and stages of cancer, with different treatments and types of management were 
included. Nevertheless, it is important to acknowledge that this study has explored fatigue and sleep 
disturbance in most types of cancer, which can provide a direction for investigating a specific type of 
cancer in future research. 
Finally, the study design does not provide data regarding fatigue and sleep disturbance present prior to 
the diagnosis of cancer. It would be important for further research to include a longitudinal study to 
identify the prevalence of fatigue and sleep disturbance before, during and after the treatment of cancer. 
Implications for Practice 
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More than 75% of the participants in this study reported significant fatigue, but most healthcare 
professionals in Oman do not assess fatigue on a regular basis. This study provides evidence that 
cancer patients in Oman experience clinically-significant fatigue that is similar to cancer patients’ 
experience elsewhere, making it advisable for healthcare professionals to conduct regular assessments 
of fatigue and provide appropriate management. In this study, approximately 75% of the participants 
were considered to be poor sleepers, with a resulting negative effect on QoL. Routine fatigue and sleep 
disturbance assessments in the clinical settings of Oman might identify patients in need of management 
strategies to reduce fatigue and improve sleep quality. 
Conclusion  
This is the first study to provide evidence of the prevalence of fatigue and sleep disturbance among 
Omani Arabic cancer patients. Fatigue and sleep disturbance were significantly related to decreased 
quality of life for this patient group. Appropriate management for fatigue and sleep disturbance in 
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Table 1: Demographic and Clinical Characteristic of Participants with Fatigue and Sleep Disturbance Scores:   
      
Non-fatigued 
(FACT-F ˃ 34) 
(n=83) (22.5%) 
Fatigued 
(FACT-F ≤ 34) 
(n=286) (77.5%)     
Poor Sleeper 
(PSQI ˃ 5) 
n=288 (78%) 
Good Sleeper 
(PSQI ≤ 5) n=81 
(22%)     
  n % n % n % (df) ꭓ2   P n % n % (df) ꭓ2 P 
Gender       (1) 0.531 .41     (1).834 .361 
Male 124 33.6 31 37.3% 93 32.5%   93 32.3% 31 38.3%   
Female 245 66.4 52 62.7% 193 67.5%   195 67.7% 50 61.7%   
Age       (4)14.399 .006     (4)6.793 .147 
18-30 36 9.8 10 12% 26 9.1%   26 9% 10 12.3%   
31-40 84 22.8 23 27.7% 61 21.3%   60 20.8% 24 29.6%   
41-50 95 25.7 30 36.1% 65 22.7%   72 25% 23 28.4%   
51-60 76 20.6 11 13.3% 65 22.7%   64 22.2% 12 14.8%   
More than 60 78 21.1 9 10.8% 69 24.1%   66 22.9% 12 14.8%   
Marital Status       (2)2.625 .269     (2)8.583 .014 
Married 273 74 62 74.7% 211 73.8%   214 74.3% 59 72.8%   
Single 40 10.8 12 14.5% 28 9.8%   25 8.7% 15 18.5%   
Divorced/ Separated 
/widowed 
56 15.2 9 10.8% 47 16.4% 
  





    
(3)2.03 .566     (3)1.130 .77 




17 20.5% 72 25.2% 
  





28 33.7% 76 26.6% 
  
78 27.1% 26 32.1% 
  




    
(2)1.558 .159     (2)1.998 .368 
Employed 125 33.9 24 28.9% 101 35.3%   99 34.4% 26 32.1%   
Retired 71 19.2 19 22.9% 52 18.2%   51 17.7% 20 24.7%   
Unemployed 173 46.9 40 48.2% 133 46.5%   138 47.9% 35 43.2%   
Cancer Site       (9)18.276 .032     (9)17.163 .046 
Breast 139 37.7 42 50.6% 97 33.9%   102 35.4% 37 45.7%   
23 
 
Colorectal 54 14.6 9 10.8% 45 15.7%   46 16% 8 9.9%   
Stomach 18 4.9 6 7.2% 12 4.2%   16 5.6% 2 2.5%   
Others 29 7.9 8 9.6% 21 7.3%   19 6.6% 10 12.3%   
Lung 20 5.4 1 1.2% 19 6.6%   19 6.6% 1 1.2%   
Gastrointestinal 19 5.1 2 2.4% 17 5.9%   17 5.9% 2 2.5%   
Brain 19 5.1 2 2.4% 17 5.9%   17 5.9% 2 2.5%   
lymphoma 20 5.4 3 3.6% 17 5.9%   16 5.6% 4 4.9%   
Gynaecological 24 6.5 2 2.4% 22 7.7%   19 6.6% 5 6.2%   
Urinary 27 7.3 8 9.6% 19 6.6%   17 5.9% 10 12.3%   
Stage       (4)2.717 .606     (4)6.667 .155 
One 34 9.2 11 13.3% 23 8%   25 8.7% 9 11.1%   
Two 145 39.3 29 34.9% 116 40.6%   107 37.2% 38 46.9%   
Three 107 29 25 30.1% 82 28.7%   87 30.2% 20 24.7%   
Four 72 19.5 15 18.1% 57 19.9%   62 86.1% 10 13.9%   




    
(3)8.65 .034     (3)1.067 .785 
< 12 months 157 42.5 26 31.3% 132 46.2%   122 42.4% 36 44.4%   
12-24 months 127 34.4 29 34.9% 97 33.9%   102 35.4% 24 29.6%   
25-36 months 52 14.1 17 20.5% 35 12.2%   39 13.5% 13 16%   





    
(2)10.791 .005     (2)10.044 .007 
Chemo and Radio 234 63.4 40 48.2% 194 67.8%   192 66.7% 42 51.9%   
Chemotherapy 122 33.1 39 47% 82 28.7%   89 30.9% 32 39.5%   
Radiotherapy 13 3.5 4 4.8% 10 3.5%   7 2.4% 7 8.6%   
Comorbidities       (6)23.153 .001     (6)24.961 <.001 
None 193 52.3 61 73.5% 132 46.2%   133 46.2% 60 74.1%   
Asthma 8 2.2 0 0% 8 2.8%   8 2.8% 0 0.0%   
Anemia 13 3.5 0 0% 13 4.5%   13 4.5% 0 0.0%   
Diabetes 21 5.7 5 6% 16 5.6%   16 5.6% 5 6.2%   
Hypertensive/ 
Heart Failure 
61 16.5 9 10.8% 52 18.2%   51 17.7% 10 12.3%   
Diabetes/Heart 
diseases 
60 16.3 6 7.2% 54 18.9%   56 19.4% 4 4.9%   









(FACT-F ˃ 34) 
(n=83) 
Fatigued 
(FACT-F ≤ 34) 
(n=286)    
  Mean SD Mean SD t df p 
C1: Subjective sleep quality .66 .65 1.5 .96 -9.199 196 <.001a 
C2: Sleep latency  1.18 .86 2 .84 -7.725 367 <.001 
C3: Sleep duration 1 .88 1.2 .81 -1.891 367 .06 
C4: Habitual sleep efficiency .67 1.03 1.05 1.07 -2.821 367 .005 
C5: Sleep disturbances  1.31 .54 1.76 .66 -6.243 159 <.001a 
C6: Use of sleep medications  .34 .65 1.13 1.08 -8.311 225 <.001a 
C7: Daytime dysfunction .59 .64 1.6 .86 -11.563 175 <.001a 
PSQI Global score 5.76 2.95 10.23 3.99 11.16 178 <.001a 
         
Physical well-being  21.24 5.7 9.48 7 -15.67 161 <.001a 
Social well-being  23.95 5.14 21.95 4.24 -3.61 367 <.001a 
Emotional well-being  20.81 2.68 13.6 5.29 -16.8 273 <.001a 
Functional well-being 23.78 5.17 17.98 5.29 -8.96 136 <.001a 
Overall Quality of Life  89.78 11.48 63.01 15.51 -17.17 177 <.001a 


















Table 3 The Effect of Sleep Versus Poor Sleep on Scores for FACT-G Subscale and FACT-F  
 
Good Sleeper 
(PSQI ≤ 5) n=81 
Poor Sleeper 
(PSQI ˃ 5) n=288    
 Mean SD Mean SD t df p 
FACT-F 34.38 11.63 19.41 11.37 10.41 367 <.001 
        
FACT-G 84.64 15.1 64.64 16.9 10.25 141.37 <.001a 
        
Physical well-being 19.32 6.65 10.1 7.61 9.89 367 <.001 
Social well-being 23.2 5.52 22.17 4.19 1.82 367 .069 
Emotional well-being 19.26 4.51 14.08 5.47 8.68 152.54 <.001a 
Functional well-being 22.85 5.68 18.28 5.42 6.64 367 <.001 
























Table 4: Logistic Regression Results for Predictors of Fatigue (FACT-F ≤ 34) Odds Ratio (95% 
CI): 









(77.5%)   
  n% n% OR (95% CI) p value 
Gender      
Male 124(33.6) 31(37.3) 93(32.5) .144(.026-.788) .025 
Age      
18-30 36(9.8) 10(12) 26(9.1) .022(.001-.899) .044 
Employment 
Stats 
     
Employed 125(33.9) 24(28.9) 101(35.3) 9.658(1.583-58.934) .014 
Month Since 
Diagnosis 
     
< 12 months 157(42.5) 132(46.2) 26(31.3) 10.902(1.369-86.82) .024 
Type of Treatment 
Finished 
     
Chemotherapy 122(33.1) 39(47) 82(28.7) .05(.005-.532) .013 
      
Physical WB Mean (SD) 21.24(5.70) 9.48(7.00) .855(.784-.933) <.001 
Social/Family WB Mean (SD) 23.95(5.14) 21.95(4.24) 1.216(1.059-1.397) .006 
Emotional WB Mean (SD) 20.81(2.68) 13.60(5.29) 0.773(.661-.904) .001 
Functional WB Mean (SD) 23.78(5.17) 17.98(5.29) 0.808(.703-.929) .003 
C2 Sleep latency Mean (SD) 1.18(.86) 2.00(.84) 3.541(1.715-7.309) .001 
C3 Sleep duration Mean (SD) 1.00(.88) 1.20(.81) 0.343(.139-.845) .02 
C5 Sleep 
disturbances 
Mean (SD) 1.31(.54) 1.76(.66) 2.713(1.079-6.82) .034 
a Variable(s) entered on step 1: Gender, Age, Marital Status, Education Level, Employment 
Stats, Cancer Site, Stage, Month Since Diagnosis, Type of Treatment Finished, 
comorbidities, Physical WB, Social/Family WB, Emotional WB, Functional WB, C1 
Subjective sleep quality, C2 Sleep latency, C3 Sleep duration, C4 Habitual sleep efficiency, 











Table 5: Logistic Regression Results for Predictors of Poor Sleeper (PSQI ˃5) Odds Ratio (95% 
CI):  
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Age  n% n% OR (95% CI) p value 
18-30 36(9.8) 10(12.3) 26(9) 10.09(1.09-93.09) .04 
Marital Status      
Single 40(10.8) 15(18.5) 25(8.7) .09(.01-.59) .01 
Physical WB Mean (SD) 19.32(6.65) 10.1(7.61) .93(.87-.99) .02 
FACT-F  Mean (SD) 34.38(11.63) 19.41(11.37) .93(.89-.97) < .001 
Variable(s) entered on step 1: Gender, Age, Marital Status, Education Level, Employment Stats, 
Cancer Site, Stage, Month Since Diagnosis, Type of Treatment Finished, comorbidities, Physical WB, 
Social/Family WB, Emotional WB, Functional WB, Fatigue Subscale. 
 
 
 
